Quanterix Corp
NASDAQ:QTRX
Net Margin
Quanterix Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Quanterix Corp
NASDAQ:QTRX
|
254.9m USD |
-35%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
154.1B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
142.3B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
70.9T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.6B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.3B USD |
9%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
190.1B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.4B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.8B EUR |
7%
|
Quanterix Corp
Glance View
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Quanterix Corp's most recent financial statements, the company has Net Margin of -35.2%.
You don't have any saved screeners yet